InterMune continues its exploration of the potential treatments for idiopathic pulmonary fibrosis (IPF), a serious condition that affects approximately 80,000 adults in the United States and more than 60,000 adults in Europe.

Both CAPACITY trials will assess the safety and efficacy of pirfenidone compared with placebo treatment in patients with IPF.

Two phase 3, randomized, double-blind, placebo-controlled safety and efficacy studies in patients with IPF.

• Approximately 720 patients will be enrolled at centers around the world
• Patients are randomly assigned to receive either Pirfenidone or placebo

Primary: Change in percent predicted FVC from baseline to week 72.
Secondary: Changes in lung function, symptoms, functional status, and quality of life.

If you need further information regarding these trials please call the InterMune Medical Information Department at 1-888-486-6411 (1-888-ITMN-411).